Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
View Release
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
View Release
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy
View Release